STOCK TITAN
  1. Home
  2. News
  3. WINT

Windtree Therapeutics Inc - WINT STOCK NEWS

Welcome to our dedicated news page for Windtree Therapeutics (Ticker: WINT), a resource for investors and traders seeking the latest updates and insights on Windtree Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Windtree Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Windtree Therapeutics's position in the market.

News
Windtree Therapeutics Announces Reverse Stock Split
Rhea-AI Summary
Windtree Therapeutics, a biotechnology company, announced a 1-for-18 reverse stock split to increase market price per share and comply with Nasdaq listing requirements. The split will reduce outstanding shares from 9.2 million to 0.5 million, with proportional adjustments to convertible notes, preferred stock, restricted stock units, and stock options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
stock split
-
News
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
Rhea-AI Summary
Windtree Therapeutics, Inc. reported its financial results for Q4 and year-end 2023, highlighting key business updates. The company acquired a novel oncology preclinical aPKCi inhibitor platform, entered into partnerships for istaroxime development, and renewed collaborations. Financially, R&D expenses decreased, while operating losses and net losses improved compared to the previous year. Cash and cash equivalents stood at $4.3 million with current liabilities at $4.0 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
Rhea-AI Summary
Windtree Therapeutics, Inc. announced the acquisition of assets from Varian Biopharmaceuticals, Inc., including a novel protein kinase inhibitor with potential in oncology and rare malignant diseases. The Company completed a $1.5 million convertible note bridge financing to support this acquisition. The acquired asset platform includes two formulations: VAR-101 (topical) and VAR-102 (oral). Windtree issued 5,500 shares of Series B Convertible Preferred Stock to Varian's creditor investors. The Company plans to pay up to $2.3 million in milestone payments for regulatory and clinical development achievements. The acquired protein kinase inhibitor targets the PKC family, specifically aPKCi, showing promising pre-clinical data in various tumor types. Windtree aims to leverage this acquisition to enhance its product candidate portfolio and advance its development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.76%
Tags
acquisition
News
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
Rhea-AI Summary
Windtree Therapeutics, Inc. renews partnership with Chang Gung University in Taiwan to further research on SERCA2a, an important target for the Company’s cardiovascular portfolio. The collaboration includes istaroxime and next-generation compounds called SERCA2a activators. Windtree believes SERCA2a activation could represent an important advancement in heart failure treatment. Istaroxime is being studied in the Phase 2 SEISMiC Extension Study in early cardiogenic shock. Market research revealed a high demand for new drug innovation to treat cardiogenic shock patients, with an estimated worldwide total market value of $1.25 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
none
-
News
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
Rhea-AI Summary
Windtree Therapeutics, Inc. has engaged Ladenburg Thalmann & Co. Inc. to evaluate strategic alternatives with the goal of maximizing stockholder value. The company has made significant progress in advancing its cardiovascular portfolio, including clinical trials in cardiogenic shock and a licensing deal with Lee’s Pharmaceuticals for the Greater China-Asia Pacific region. Windtree is actively exploring strategic alternatives such as acquisition, merger, further licensing, or company sale to maximize shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
none
-
News
Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company
Rhea-AI Summary
Windtree Therapeutics (NASDAQ:WINT) has announced a significant agreement with Deerfield Management Company to retire a $15 million liability associated with its Aerosurf drug and device combination treatment for premature infants. The company has strengthened its financial position and balance sheet, with no significant debt and increased shareholder equity. Windtree is also targeting Phase 3 readiness in cardiogenic shock with its lead asset istaroxime, which has shown promising results in a phase 2 study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
none
News
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
Rhea-AI Summary
Windtree Therapeutics, Inc. has entered into an Exchange and Termination Agreement with Deerfield Management Company to terminate its rights to receive up to $15,000,000 in development and commercial milestone payments associated with AEROSURF®. In exchange, Windtree will issue 608,272 shares of common stock and pay Deerfield $100,000 in cash. The company also agreed to pay an additional $100,000 upon meeting certain conditions. Windtree's President and CEO, Craig Fraser, expressed appreciation for Deerfield's support and stated that the company has strengthened its balance sheet, reduced cash burn rate, and made progress in clinical trials for its lead asset, istaroxime.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
none
-
News
Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China
Rhea-AI Summary
Windtree Therapeutics Inc. (NASDAQ:WINT) has entered into a license agreement with Lee's Pharmaceutical (HK) Ltd. to develop and commercialize its product candidate istaroxime for acute heart failure and cardiogenic shock in the greater China region. The deal supports Windtree's pipeline treatments for acute heart failure and cardiogenic shock and has the potential to provide financial support for development of treatment to address an unmet need and a growing problem in China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region
Rhea-AI Summary
Windtree Therapeutics, Inc. has entered into a license agreement with Lee’s Pharmaceutical (HK) Limited for the development and commercialization of istaroxime in Greater China, including for acute heart failure and cardiogenic shock. The agreement also includes the licensing of Windtree’s next-generation SERCA2a activators and rostafuroxin. Lee’s will fund Phase 3 for istaroxime and will be responsible for all development, manufacturing, regulatory, and commercial costs for the covered products in the licensed region. Windtree is entitled to receive up to $138.1 million in payments upon the achievement of certain milestones plus up to low double-digit royalties. The agreement also establishes joint committees to oversee regional development and commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.64%
Tags
none
News
Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator
Rhea-AI Summary
Windtree Therapeutics, Inc. (WINT) announced new preclinical data on the Company’s lead product candidate, istaroxime, and another preclinical pipeline drug candidate, CVie-216, showing reductions in ventricular arrythmias in a rat heart model of diabetes with restricted and restored coronary blood flow induced injury.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.43%
Tags
none
Stock WINT logo
Windtree Therapeutics Inc

Nasdaq:WINT

WINT Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

WINT Stock Data

3.99M
4.55M
4.65%
12.91%
0.43%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Warrington

About WINT

windtree therapeutics, inc. is a biotechnology company focused on developing novel kl4 surfactant therapies for respiratory diseases and other potential applications. windtree’s proprietary technology platform includes a synthetic, peptide-containing surfactant (kl4 surfactant ) that is structurally similar to human pulmonary surfactant — and novel drug-delivery technologies that are being developed to enable noninvasive administration of aerosolized kl4 surfactant. windtree is focused initially on improving the management of respiratory distress syndrome (rds) in premature infants as surfactant therapy has been shown to save lives in this condition. windtree believes that its proprietary technologies may make it possible, over time, to develop a pipeline of kl4 surfactant product candidates to address a variety of respiratory diseases for which there are few or no approved therapies and, in doing so, potentially deliver a lifetime of hope to patients and their families.